PatientsVille.com Logo


Renitec Medical Research Studies

Up-to-date List of Renitec Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Renitec Medical Research Studies

Rank Status Study
1 Recruiting Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: enalapril maleate
Outcome Measures: Increase or decrease in doxorubicin hydrochloride exposure;   Change in b-type natriuretic peptide, cardiac troponins, and urine microalbumin after infusion with doxorubicin hydrochloride;   Effect of enalapril maleate on the formation of the doxorubicin hydrochloride metabolite, doxorubicinol
2 Recruiting Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure
Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy;   Drug: Aliskiren monotherapy;   Drug: Aliskiren / Enalapril combination therapy
Outcome Measures: Delaying time to first occurrence of either cardiovascular death or heart failure hospitalization in patients with chronic heart failure;   Reduction in the BNP level from baseline to predefined timepoint;   Improvement in the clinical summary score (assessed by KCCQ) from baseline to predefined timepoint.
3 Recruiting An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Condition: Hypertension
Interventions: Drug: Aliskiren;   Drug: Enalapril
Outcome Measures: Evaluate the safety and tolerability (by measuring vital signs, AE, SAEs and safety laboratories) of long term administration of aliskiren compared to enalapril in hypertensive children aged 6-17 years old.;   Mean sitting systolic blood pressure reduction of long-term administration of aliskiren compared to enalapril in hypertensive children aged 6-17 years old;   Evaluate the efficacy as assessed by calculated mean arterial pressure (MAP), of long-term administration of aliskiren compared to enalapril in hypertensive children 6 to 17 years old;   Mean sitting diastolic blood pressure reduction of long-term administration of aliskiren compared to enalapril in hypertensive children aged 6-17 years old
4 Unknown  The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Condition: Continuous Ambulatory Peritoneal Dialysis
Interventions: Drug: Enalapril;   Drug: Enalapril plus Losartan;   Drug: Placebo
Outcome Measures: Change in dialysate CA-125 and modified peritoneal equilibrium test;   Dialysis adequacy, residual renal function, hospitalization, peritonitis episodes, any adverse drug effects, death from any cause
5 Unknown  Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia
Condition: Diabetic Macular Ischemia
Interventions: Drug: enalapril;   Other: oxygen;   Drug: placebo
Outcome Measure:
6 Recruiting Mitigation of Radiation Pneumonitis and Fibrosis
Conditions: Lung Cancer;   Radiation Pneumonitis
Interventions: Drug: Enalapril;   Drug: placebo
Outcome Measures: Radiation pneumonitis;   Radiation fibrosis;   Cancer recurrence and cancer-related survival
7 Not yet recruiting Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy
Conditions: Microalbuminuria;   Sickle Cell Nephropathy
Interventions: Drug: Enalapril;   Drug: N-Acetylcysteine
Outcome Measures: urinary albumin excretion rate;   Glomerular filtration rate
8 Recruiting Pharmacogenetics of Ace Inhibitor-Associated Angioedema
Conditions: Hypertension;   Diabetes Type 2
Interventions: Drug: Sitagliptin;   Drug: Substance P,;   Drug: bradykinin;   Drug: enalaprilat;   Drug: Glucagon-like peptide 1;   Drug: brain natriuretic peptide
Outcome Measures: The effect of enalaprilat, sitagliptin, or the combination on the vasodilator response (forearm blood flow) to substance P and bradykinin (Group 1) or glucagon like peptide-1 and brain naturetic peptide (Group 2).;   Assess peptide concentrations, nitric oxide metabolites, tissue type plasminogen activator, glucose, and catecholamines
9 Unknown  Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
Conditions: Kidney Failure, Chronic;   Cardiovascular Diseases
Interventions: Drug: Candesartan and enalapril;   Drug: candesartan and enalapril
Outcome Measures: pulse wave velocity (aortic and brachial);   augmentation index;   blood pressure (brachial and aortic);   buckbergs index;   time to reflection;   pulse pressure;   change in glomerular filtration rate (GFR);   blood parameters
10 Recruiting Prevention of Anthracycline-induced Cardiotoxicity
Condition: Cancer
Intervention: Drug: Enalapril
Outcome Measures: the occurrence of cTn elevation above the threshold in use at the local laboratory, at any time during the study;   admissions to hospital for cardiovascular causes,;   cardiovascular deaths;   occurrence of hypo- or hyperkinetic arrhythmias
11 Unknown  The Acute Effects of the Angiotensin-Converting Enzyme Inhibitor Enalaprilat on Flow Distribution
Conditions: Hypertension;   Congestive Cardiomyopathy
Intervention: Drug: Enalaprilat
Outcome Measure: The acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary, and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
12 Unknown  Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Enalapril;   Drug: Calcium Supplement
Outcome Measures: Proteinuria;   Estimated GFR;   All cause mortality;   Cardiovascular mortality
13 Unknown  The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients
Condition: Peritoneal Membrane Failure
Interventions: Drug: placebo;   Drug: Aliskiren;   Drug: Aliskiren plus Losartan;   Drug: Enalapril plus Losartan
Outcome Measures: Changing in modified peritoneal equilibrium test;   appearance rate of dialysate CA125;   nutritional status;   adverse events
14 Unknown  Aspirin and Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients
Conditions: Diabetes Mellitus;   Microalbuminuria
Intervention: Drug: aspirin
Outcome Measures: urinary albumin excretion;   glomerular filtration rate
15 Recruiting Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Condition: Hypertension Secondary to Kidney Transplant
Intervention: Drug: New Medication: Enalapril, Isradipine, Propranolol
Outcome Measures: Proportion of subjects in each of the treatment arms who change from non-dipper to dipper status;   Change in night-time systolic/diastolic blood pressure;   Change in left ventricular mass index;   Change in albumin:creatinine ratio;   Change in estimated glomerular filtration rate;   Change in pulse wave velocity;   Association of serum adiponectin levels and SNPs of adiponectin with outcomes
16 Unknown  Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human
Condition: Heart Failure
Intervention: Drug: Enalapril
Outcome Measures: The primary outcomes are the mean changes in the Rho-kinase activity in leukocytes before and after periods of treatment.;   The correlation between the mean changes in Rho-kinase activity in leukocytes and cardiac function measured by echocardiography.
17 Recruiting The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)
Condition: CKD II-III
Interventions: Drug: Eplerenone;   Drug: Placebo
Outcome Measure: Angiotensin levels (pg/ml) of CKD II-III patients with DM II with eplerenone additional to enalapril in comparison to patients who receive a placebo on top of enalapril therapy.
18 Not yet recruiting Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Condition: Hypertension
Interventions: Drug: Take ACE-I;   Drug: Hold ACE-I
Outcome Measures: Intraoperative Hypotension;   Acute Renal Failure;   Low blood pressure subgroup;   Older age subgroup;   Postoperative Hypertension
19 Recruiting Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)
Conditions: Ischemic Stroke;   High Blood Pressure
Interventions: Drug: Low-dose rtPA;   Drug: Standard-dose rtPA;   Other: Intensive blood pressure (BP) lowering;   Other: BP management policies
Outcome Measures: Combined death and any disability;   Symptomatic intracerebral hemorrhage;   Intracerebral hemorrhage of any type in CT scans;   Death or disability by the alternative, but less widely used, shift analysis;   Death;   Disability;   Neurological deterioration;   Health-related quality of life;   Admission to residential care;   Health service use
20 Not yet recruiting Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects
Conditions: Pre-diabetes;   Pre-hypertension
Interventions: Drug: Metformin+Enalapril+Simvastatin;   Drug: Placebo tablet
Outcome Measures: Cardiovascular Events;   Micro-vascular Complications;   Cumulative Incidence of Diabetes;   Cumulative Incidence of Hypertension;   Incidence of Individual Cardiovascular Disease

These studies may lead to new treatments and are adding insight into Renitec etiology and treatment.

A major focus of Renitec research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Renitec